Eden vs Henry Meds: GLP-1 Compounding Head-to-Head (May 2026)

Prices as of May 2026. Compounding legal status current as of the May 22, 2025 enforcement deadline. See our compounding tracker for weekly updates.

The short answer

Choose Eden if your primary filter is monthly cost. It is cheaper at every dose level and its flat-rate model means the advantage grows as you titrate toward maintenance dose.

Choose Henry Meds if clinical framework matters more than price. Henry has more published clinical protocols and a longer track record — at a higher ongoing cost.

The pricing gap starts meaningful at the starter dose and widens substantially at maintenance. For a patient titrating over six months, the difference can exceed $1,000 in Eden's favour.

At-a-glance comparison

Pricing from publicly published program terms as of May 2026. Verify directly before enrolling — both platforms adjust pricing periodically.

Pricing in depth

Semaglutide: Eden wins from month one

At the starter dose, Eden is $118 cheaper in the first month ($129 vs $247). On the recurring monthly rate, Eden is $88 cheaper ($209 vs $297) as long as you stay at a standard dose. That gap alone is meaningful.

The more important number is what happens at maintenance dose.

Henry Meds uses a tiered pricing structure where each dose step-up costs approximately $100 more per month. A patient who titrates from their starting dose to a mid-maintenance dose can see their monthly bill climb from $297 to $397 or beyond. The surcharge is disclosed on Henry Meds' program terms, but it is easy to miss during an intake flow that quotes only the first month's rate.

Eden charges $209/month for compounded semaglutide regardless of dose. For a patient who reaches and holds a maintenance dose, the monthly saving in Eden's favour is $188 or more — every month.

Six-month cost illustration: semaglutide, titrating to maintenance

Month	Eden	Henry Meds
1 (starter dose)	$129	$247
2–3 (mid dose)	$209	$297–$397
4–6 (maintenance)	$209	$397+
6-month total	~$1,214	~$2,082

Illustrative figures based on publicly stated pricing as of May 2026. Dose progression varies by patient; your prescriber determines your titration schedule.

Tirzepatide: Eden wins by a wider margin

For tirzepatide, Eden is cheaper from the first month: $249 vs Henry Meds' $399. Ongoing, Eden charges $329/month flat; Henry Meds starts at $449/month and applies the same dose-tier surcharge, so patients titrating to maintenance pay above $449/month. Eden's flat rate does not change. The financial case for Eden on tirzepatide is unambiguous unless clinical framework outweighs cost.

Compounding status and regulatory risk

Both Eden and Henry Meds operate under the §503A(b)(1)(D) exemption — the only active legal pathway for compounded semaglutide and tirzepatide as of May 2026. The 503B bulk-substance pathway for these drugs closed when the enforcement-discretion windows expired on May 22, 2025. For the full breakdown of what §503A(b)(1)(D) actually permits and what risks attach, see our 503A vs 503B explainer and the compounding tracker.

Neither has received an FDA warning letter

As of May 2026, neither Eden nor Henry Meds has been confirmed as a recipient of a GLP-1 compounding warning letter. The FDA issued warning letters to more than 50 compounders and manufacturers in a March 2026 enforcement wave. Henry Meds has not been confirmed among the named recipients in public records. Eden was not named either.

This is not a clean bill of health — it is an absence of confirmed enforcement action. Both platforms operate in an area of active regulatory scrutiny. The enforcement environment can shift without advance notice.

Henry Meds carries active Lilly litigation; Eden does not

Eli Lilly filed a patent-infringement and false-advertising lawsuit against Henry Meds (Adonis Health Inc) alleging that Henry marketed compounded tirzepatide as equivalent to FDA-approved Zepbound after the shortage justification ended. In 2026, a court partially denied Henry Meds' motion to dismiss: the claim that Henry used the term "personalised" in advertising survived; the "safe and effective" claim was dismissed. The case is proceeding to discovery.

Eden has not been named in confirmed Eli Lilly litigation as of May 2026. Eden was not among the defendants in Novo Nordisk's February 2026 omnibus patent suit either.

The difference matters. Active litigation is a material overhang — not because it prevents Henry Meds from operating today, but because an adverse ruling or settlement could change the terms of operation. Patients who enrol in Henry Meds now are accepting that litigation-continuity risk. Patients who enrol in Eden are accepting a different risk profile — no confirmed litigation, but a less-documented operating history.

Neither position is risk-free. Both are operating in a legally contested space. See our compounding tracker for litigation status updates.

Clinical framework

This is the dimension where Henry Meds has the stronger case.

Henry Meds has published more detailed clinical protocols than most compounding telehealth platforms in this market. Their prescriber network (Adonis Health Inc's employed and contracted providers) is documented, their titration protocols are published in patient-facing blog posts and program terms, and they have been operating long enough to accumulate an auditable public record of how they handle dose adjustments, side-effect management, and patient check-ins.

Eden's clinical framework is less publicly documented. The provider-facing infrastructure — the protocols governing titration decisions, monitoring frequency, and side-effect escalation — is less visible on Eden's public materials than on Henry Meds'. Eden does have one concrete disclosure advantage: it publicly names its four PCAB-accredited 503A compounding pharmacy partners (GoGoMeds, Precision, Enovex, and Absolute Pharmacy). Henry Meds does not publicly identify its pharmacy partners, limiting any independent quality check before you enrol. On pharmacy transparency, Eden is stronger; on clinical protocol transparency, Henry Meds is stronger.

Both platforms use async prescriber models. Neither requires a synchronous video consultation as part of the standard program.

If your weight-loss presentation is straightforward with no complex comorbidities and you are primarily cost-optimising, the clinical framework difference is unlikely to affect your outcome. If you have a complex metabolic history, prior bariatric surgery, multiple medications, or a prior adverse response to a GLP-1, Henry Meds' clinical depth is the stronger environment.

Who chooses Eden

Eden is the better fit if:

• You are primarily cost-optimising and want the lowest-sticker compounding GLP-1 platform in the market
• You expect to titrate to a mid or maintenance dose — Eden's flat rate means no cost surprises as you escalate
• You want named pharmacy partners and PCAB accreditation transparency before enrolling
• You are on tirzepatide — Eden's $329/month flat rate is meaningfully cheaper than Henry Meds at every dose
• You are not comfortable with the additional legal exposure from Henry Meds' active Lilly litigation

Be cautious about Eden if:

• You have a complex metabolic history or multiple comorbidities — Henry Meds' more developed clinical framework is the better clinical environment
• You want the lowest possible risk from an operational-continuity standpoint — Henry has a longer public track record, for whatever that is worth in an unsettled regulatory environment

Who chooses Henry Meds

Henry Meds is the better fit if:

• Clinical framework depth matters more than price — Henry has more published protocols and a more auditable prescribing record
• You are starting at a low dose and expect to stay there — the cost gap is smaller at starter doses, and the $100/tier surcharge only bites as you escalate
• You want a provider with a longer operating history in the compounded GLP-1 market specifically
• You are more comfortable with a well-documented clinical program than with an opaque one, even at a higher price

Be cautious about Henry Meds if:

• You plan to titrate to maintenance dose — the $100/tier surcharge erodes the cost position quickly
• The active Eli Lilly litigation creates a comfort threshold you cannot get past
• You want to know which compounding pharmacy is preparing your medication before you enrol

Verdict

Eden wins on price at every tier — first month, ongoing, and at maintenance dose. The flat-rate structure is the defining financial advantage; a patient who titrates to maintenance will pay roughly $800–$1,000 more with Henry Meds over six months.

Henry Meds wins on clinical framework — more developed published protocols, a more auditable prescribing record, and a longer operational history. For patients with clinical complexity, that matters.

Both operate under §503A(b)(1)(D) with no confirmed FDA warning letters. Henry Meds carries active Lilly litigation that Eden does not — an asymmetry in risk profiles that does not prevent Henry from operating today but is worth understanding before you enrol.

For most patients optimising on cost: Eden is the default. For patients with clinical complexity who need documented oversight and can absorb the higher price: Henry Meds is the stronger clinical environment. Neither platform eliminates the underlying regulatory risk of the 503A compounding space.

Pricing figures are sourced from provider program terms pages as of May 2026. Compounding legal status reflects the regulatory landscape as of the May 22, 2025 enforcement deadline. Litigation status is current as of April/May 2026. Neither this publication nor its editors are affiliated with Eden or Henry Meds. All affiliate relationships are disclosed inline per FTC 16 CFR 465; this article contains no affiliate links.

Related: Eden full review · Henry Meds full review · 503A vs 503B explained · Compounding tracker